Stocklytics Platform
Asset logo for symbol NRBO
NeuroBo Pharmaceuticals
NRBO67
$3.50arrow_drop_up4.25%$0.14
High Growth
Penny Stock
Asset logo for symbol NRBO
NRBO67

$3.50

arrow_drop_up4.25%

Income Statement (NRBO)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$10.08M-$6.88M-$5.66M-$3.89M-$3.80M
EBITDA-$10.07M-$6.87M-$5.66M-$3.89M-$6.87M
gross Profit-$6,000.00-$4,000.00--$1,000.00-
NET Income-$10.05M-$6.71M-$5.31M-$3.81M-$734.00K
total Revenue$0.00$0.00$4,000.00$0.00$0.00

Balance Sheet (NRBO)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt-$27.76M-$15.80M-$22.23M-$25.61M-$28.68M
stockholders Equity$18.94M$10.07M$16.68M$21.55M$25.19M
total Assets$28.75M$17.01M$22.78M$26.42M$29.17M
total Debt$170.00K$187.00K$203.00K$218.00K-
total Liabilities$9.80M$6.94M$6.09M$4.87M$3.98M

Cash Flow (NRBO)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$19.20M-$0.00$0.00-$80.00
free Cash Flow-$7.25M-$6.44M-$3.40M-$2.85M-$2.04M
investing Cash Flow-----
operating Cash Flow-$7.25M-$6.44M-$3.39M-$2.81M-$2.04M

NeuroBo Pharmaceuticals (NRBO) Financials

NeuroBo Pharmaceuticals Inc (NRBO) is a leading biopharmaceutical company that specializes in developing innovative treatments for neurological and neurodegenerative diseases. The company's financials reflect its commitment to research and development, as well as its focus on delivering value to its stockholders.
The income statement provides a snapshot of NeuroBo Pharmaceuticals Inc's financial performance over a specific period. It shows the company's revenue, expenses, and net income. The ebit (earnings before interest and taxes) and ebitda (earnings before interest, taxes, depreciation, and amortization) figures help assess the company's profitability and operational efficiency.
NeuroBo Pharmaceuticals Inc's gross profit represents the revenue left after deducting the cost of goods sold. This figure is crucial in evaluating the company's ability to generate profit from its core operations. The net income from stockholders reflects the profit available to the company's equity shareholders after deducting expenses and taxes.
The total revenue of NeuroBo Pharmaceuticals Inc encompasses all the income generated by the company, including sales of its products and services. This figure highlights the company's overall financial performance. The balance sheet provides a snapshot of the company's assets, liabilities, and stockholders' equity at a specific point in time.
Cash equivalents are highly liquid assets that can be readily converted into cash. NeuroBo Pharmaceuticals Inc's cash equivalents indicate the company's short-term liquidity and its ability to meet its financial obligations. Net debt represents the company's total debt minus its cash and cash equivalents, giving insight into its financial leverage.
Stockholders' equity represents the residual interest in the company's assets after deducting liabilities. It reflects the ownership value of the stockholders and their potential claim on the company's assets. Total assets represent all the resources owned by NeuroBo Pharmaceuticals Inc.
Total debt encompasses all the financial obligations of NeuroBo Pharmaceuticals Inc, including long-term and short-term debt. It serves as an indicator of the company's financial risk and its ability to manage its debt obligations. Total liabilities include all the obligations of the company, including debt, accounts payable, and other liabilities.
The cash flow statement provides an overview of NeuroBo Pharmaceuticals Inc's cash inflows and outflows. It helps assess the company's ability to generate cash and its cash management practices. The financing cash flow reflects the company's cash flow from financing activities, such as issuing or repurchasing stock and borrowing or repaying debt.
Free cash flow represents the cash generated by NeuroBo Pharmaceuticals Inc after deducting capital expenditures necessary to maintain or expand its business. It shows the company's ability to generate cash that can be used for dividends, share repurchases, or other investments. The investing cash flow reflects the company's cash flow from investing activities, such as acquiring or selling assets and making investments.
The operating cash flow shows the cash generated by NeuroBo Pharmaceuticals Inc from its core operations, excluding cash inflows from financing or investing activities. It provides insight into the company's ability to generate cash from its primary business activities and maintain its operations.
add NeuroBo Pharmaceuticals  to watchlist

Keep an eye on NeuroBo Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media